Clinical Trials Logo

Asthma clinical trials

View clinical trials related to Asthma.

Filter by:

NCT ID: NCT05918874 Completed - Obesity Clinical Trials

Postnatal Nutrition and Physical Activity in Obese Asthmatic Children

Start date: January 23, 2022
Phase:
Study type: Observational

The aim of this study was to compare the duration of breast milk intake, vitamin D intake, asthma control level and physical activity levels between obese asthmatic children and non-obese children. This was a prospective study in children aged 8-17 years with asthma. Asthma control level was evaluated by asthma control test and physical activity level was evaluated by Physical Activity Questionnaire for Children (IPAQ-C) and leisure time activity scale.

NCT ID: NCT05908864 Completed - Asthma Attack Clinical Trials

Nebulized Versus Intravenous Magnesium Sulfate in Treatment of Asthma Exacerbation

Start date: October 30, 2018
Phase:
Study type: Observational

A prospective study in Beni-Seuf University Hospital that was conducted on 123 adult patients with acute asthma exacerbations. Patients were classified into group (I): received IV magnesium sulfate, group (II): received nebulized magnesium sulfate, and group (III): control group. Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done for all patients before treatment, immediately after the treatment, "30", and "60" min after treatment.

NCT ID: NCT05904002 Completed - Asthmatic Clinical Trials

Effect of Incentive Spirometery on Asthmatic Pregnant Women

Start date: September 20, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effect of the incentive spirometer on asthma during pregnancy.

NCT ID: NCT05870215 Completed - Asthma Clinical Trials

Phenotyping Responses to Systemic Corticosteroids in the Management of Asthma Attacks

PRISMA
Start date: September 1, 2022
Phase:
Study type: Observational

This observational study compares the phenotypic variability (clinical and biological) in treatment response to systemic corticosteroids according to the blood eosinophil count and FeNO in physician-diagnosed ≥12-year-old asthmatics presenting with an asthma attack and healthy controls. Multimodal clinical and translational assessments will be performed on 50 physician-diagnosed, ≥12-year-old asthma patients presenting with an asthma attack and 12 healthy controls. These will include a blood eosinophil count, FeNO, and testing for airway infection (conventional sputum cultures and POC nasopharyngeal swabs). People with asthma will be assessed on day 0 and after a 7-day corticosteroid course, with in-home monitoring performed in between.

NCT ID: NCT05855512 Completed - Asthma in Children Clinical Trials

Impact of Nurse-led Intervention on Asthma Control in Children

Start date: July 27, 2020
Phase: N/A
Study type: Interventional

This randomized control trial design (RCT) study was conducted on children aged 6 -11 years

NCT ID: NCT05850494 Completed - Asthma Clinical Trials

Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma

Start date: May 2, 2023
Phase: Phase 3
Study type: Interventional

A study to assess bronchospasm potentially induced by HFO MDI as compared with HFA MDI in participants with well controlled or partially controlled asthma

NCT ID: NCT05830071 Completed - Asthma Clinical Trials

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Start date: March 29, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the potential for cardiac repolarization, according to electrocardiographic monitoring (including QT and QTc intervals), of two dose levels of CHF5993 pMDI (beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB)) and of one dose of CHF5259 (GB) in healthy subjects compared to moxifloxacin and placebo.

NCT ID: NCT05824936 Completed - Asthma in Children Clinical Trials

Enhanced Community-Based Asthma Monitoring Through Novel Technology

EMT
Start date: June 8, 2023
Phase: N/A
Study type: Interventional

The goal of this pilot interventional study is to learn about the implementation of a home monitoring program (using remote study visits and lung function testing) in children with asthma. The main questions to answer are: 1. Do participants find the program to be feasibile, acceptable and accessible? 2. What factors are associated with completion of the program? 3. Does the program have an effect on asthma control and daytime sleepiness?

NCT ID: NCT05813470 Completed - Allergic Asthma Clinical Trials

Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma

Start date: January 18, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Omalizumab produced by CinnaGen compared with Xolair® (Genentech, Inc., USA And Novartis Pharmaceuticals Corp, Switzerland) in subjects with uncontrolled Moderate to Severe Allergic Asthma All the participants will receive one of the following regimens: Omalizumab (CinnaGen) or Xolair® (Genentech, Inc., USA And Novartis Pharmaceuticals Corp, Switzerland), as subcutaneous injections, Omalizumab was administered every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg/IgE for a duration of 28 weeks The primary objective of this study is to assess whether the efficacy of Omalizumab (CinnaGen, Iran) is equivalent to Xolair® (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) as measured by rate of protocol-defined asthma exacerbations during the 28-week treatment period

NCT ID: NCT05791565 Completed - Asthma Clinical Trials

Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants

Start date: April 3, 2023
Phase: Phase 1
Study type: Interventional

This study will be conducted to compare the PK of salbutamol administered via metered dose inhalers (MDI) containing propellants 1,1-difluroethane (HFA-152a) and 1,1,1,2-tetrafluoroethane (HFA-134a) in healthy participants.